Chang 2008.

Study characteristics
Methods	Study design: RCT Number randomized: 24; 12 to the exercise group and 12 to the control group Study start and stop dates: not reported Length of intervention: 3 weeks Length of follow‐up: to end of the intervention
Participants	Type cancer: AML Time since cancer diagnosis: not reported Time in active treatment: not reported Inclusion criteria: Aware of diagnosis Prescribed chemotherapy: specifically, induction therapy with cytarabine 100 mg/m2/day by continuous intravenous infusion for 7 days and idarubicin 12 mg/m2/day by intravenous push on days 1, 2, and 3 Performance status 0 to 3 on ECOG Eligibility criteria related to interest or ability, or both, to exercise: none Exclusion criteria: none Gender, n (%): exercise group: male, 8 (72.7%); female, 3 (27.3%) control group: male, 4 (36.4%); female, 7 (63.6%) Current age, mean (SD) years: exercise group: 49.4 (15.3) years control group: 53.3 (13.6) years Age at cancer diagnosis: not reported Ethnicity/race: not reported Education level: not reported SES: not reported Employment status: not reported Comorbidities: not reported Past exercise history: not reported On hormone therapy: not reported
Interventions	12 participants assigned to the exercise intervention, including: walking exercise program consisted of 12 minutes' supervised walking in the hospital hallway on 5 days per week Type exercise (aerobic/anaerobic): aerobic Intensity of the experimental exercise intervention: target HR = resting + 30 Frequency: 5 days per week Duration of individual sessions: 12 minutes Duration of exercise program: 3 weeks Total number of exercise sessions: 15 sessions Format: individual Facility: hospital Professionally led by an Masters‐prepared nurse research assistant, who accompanied patient on walk Adherence: not reported 12 participants assigned to control group, including: visit by trained research assistant to maintain same patient contact Contamination of control group: not reported
Outcomes	No primary outcome was identified. QoL outcomes included: fatigue, measured using the BFI, and subscales: fatigue intensity fatigue interference 12‐MWT overall symptom distress, assessed using the Symptom Distress Scale Modified Form mood disturbance, assessed using the Profile of Moods State short‐form Outcomes were measured at baseline, 1 week, 2 weeks, and 3 weeks: exercise group: n = 11 at baseline and all subsequent time points control group: n = 11 at baseline and at all subsequent time points Subgroup analysis: none Adverse events: not reported
Notes	Country: Taiwan Funding: none reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	The generation of the random sequence was not described
Allocation concealment (selection bias)	Unclear risk	Whether the treatment assignment was concealed from study personnel and participants was not described
Blinding of participants and personnel (performance bias) All outcomes	High risk	Owing to the nature of the intervention, it was not possible to conceal allocation to the intervention from the participants
Blinding of outcome assessment (detection bias) All outcomes	High risk	Allocation to the intervention was not concealed from the study personnel
Incomplete outcome data (attrition bias) All outcomes	High risk	1 participant from the exercise group and 1 from the control group were not included in any analyses
Selective reporting (reporting bias)	Low risk	There is no evidence of selective reporting of outcomes
Other bias	Low risk	The trial appears to be free of other problems that could put it at a high risk of bias